Does pharmacotherapy for attention-deficit/hyperactivity disorder predict risk of later major depression?

W. Burleson Daviss, Boris Birmaher, Rasim S. Diler, James Mintz

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

Objective: This study's goal was to determine among youths with attention-deficit/hyperactivity disorder (ADHD) how the history of ADHD pharmacotherapy influenced the risk of developing major depressive disorder (MDD), compared to other commonly reported predictors. Method: Diagnostic and treatment history data were analyzed retrospectively in 75 youths 11-18 years old with definite or probable ADHD, enrolled in an observational study at a tertiary mental health clinic. Subjects with histories of MDD (H/o MDD) (n = 36) were compared to others who had never been depressed (Never-Depressed) (n = 39) regarding histories of ADHD pharmacotherapy, psychopathology and other potential covariates of MDD risk. Results: H/o MDD subjects reported longer delays before initiating ADHD pharmacotherapy, were more often female, reported having experienced more traumatic event types, and had higher rates of early anxiety and externalizing disorders. With all covariates allowed to enter a backward stepwise Cox regression of survival time till first episodes of MDD, only two variables remained in the model. The time-dependent variable, ADHD pharmacotherapy, prolonged survival times (p = .012), while having experienced more traumatic event types shortened them (p = .001). Conclusions: This study provides preliminary evidence that pharmacotherapy for ADHD may have a protective effect in ADHD youths, reducing the risk of later MDD.

Original languageEnglish (US)
Pages (from-to)257-264
Number of pages8
JournalJournal of Child and Adolescent Psychopharmacology
Volume18
Issue number3
DOIs
StatePublished - Jun 1 2008

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Does pharmacotherapy for attention-deficit/hyperactivity disorder predict risk of later major depression?'. Together they form a unique fingerprint.

Cite this